Publications

List of the manuscripts published or in preparation from the Laakkonen Lab (updated on 19.10.2020)

Scientists from the Laakkonen lab are identified in bold.

Under preparation

Karhemo PR, Filppu P, Laine A, Sihto H, Bono P, Joensuu H, Westermarck J and Laakkonen P. Nucleophosmin T199 phosphorylation correlates with CIP2A expression and poor survival of breast cancer patients.

International scientific journals with referee practice

Kadekar S, Nawale G, Rangasami V, Le Joncour V, Laakkonen P, Hilborn J, Varghese Oommen O, Oommen P. Redox Responsive Pluronic Micelle Mediated Delivery of Functional siRNA: A Modular Nano-Assembly for Targeted Delivery. Submitted to ACS Macro Letters.

Prabhakar N, Merisaari J, Le Joncour V, Peurla M, Sen Karaman D, Casals E, Laakkonen P, Westermarck J and Rosenholm JM. Circumventing drug treatment? Polyethylenimine functionalized nanoparticles inherently and selectively kill patient-derived glioblastoma stem cells. Submitted to ACS Macro Letters.

Ayo A, Figueras E, Schachtsiek T, Budak M, Sewald N and Laakkonen P. Tumor-targeting peptides: The functional screen of glioblastoma homing peptides to the target protein FABP3 (MDGI). Cancers (Basel) 12(7):E1836, 2020.

Tanjore Ramanathan J, Lehtipuro S, Sihto H, Tovari J, Reiniger L, Téglasi V, Loldvay J, Nyketer M, Hannu Haapasalo, Le Joncour V and Laakkonen P. Vascular expression of Prostate Specific Membrane Antigen in primary lung carcinomas associates with faster metastatic dissemination to brain. J Cell Mol Med 24(12):6916-6927, 2020.

Eriksson J, Le Joncour V, Jahkola T, Juteau S, Laakkonen P, Saksela O and Hölttä E. Prolyl t-hydroxylase subunit alpha 1 (P4HA1) is a poor prognosis biomarker in primary melanomas and its depletion inhibits melanoma cell invasion and disrupts tumor blood vessel formation. Mol Oncol 14(4):742-762, 2020.

Barok M, Le Joncour V, Martins A, Isola J, Salmikangas M, Laakkonen P* and Joensuu H*. ARX-788, a novel anti-HER2 antibody-drug conjugate, shows strong anti-tumor effect in preclinical models of HER2-positivie breast cancer and gastric cancer with trastuzumab entansine-resistance. *Shared last authorship. Cancer Lett 473:156-163, 2020.

Merisaari J, Denisova O, Doroszko M, Le Joncour V, Johansson P, Leenders WPJ, Kastrinsky DB, Zaware N, Narla G, Laakkonen P, Nelander S, Ohlmeyer M and Westermarck J. Preclinical monotherapy efficacy of blood-brain barrier permeable small molecule activators of tumor suppressor PP2A in glioblastoma. Brain Communications 2(1):fcaa002, 2020.

Le Joncour V, Martins A, Puhka M, Isola J, Salmikangas M, Laakkonen P*, Joensuu H* and Barok M*. A Novel Anti-HER2 Antibody-Drug Conjugate XMT-1522 for HER2-Positive Breast and Gastric Cancers Resistant to Trastuzumab Emtansine. *Shared last authorship. Mol Cancer Ther 18(10):1721-1730, 2019.

Le Joncour V, Filppu P, Hyvönen M, Holopainen M, S. Turunen P, Sihto H, Burghardt I, Joensuu H, Tynninen O, Jääskeläinen JE, Weller M, Lehti K, Käkelä RT and Laakkonen P. Vulnerability of invasive glioma cells to lysosomal membrane destabilization. EMBO Mol. Med. E9304, 2019.

Figueras E, Martins A, Borbély A, Le Joncour V, Cordella P, Perego R, Modena D, Pagani P, Esposito S, Auciello G, Frese M, Gallinari P, Laakkonen P, Steinkühler C and Sewald N. Octreotide Conjugates for Tumor Targeting and Imaging. Pharmaceutics 11, 220, 2019.

Le Joncour V, Karaman S and Laakkonen P. Predicting in vivo payloads delivery using a Blood-Brain Tumor-Barrier on a dish J Vis Exp. Apr 16;(146), 2019.

Pulkka O-P, Gebreyohannes Y, Wozniak A, Mpindi J-P, Tynninen O, Icay K, Cervera A, Keskitalo S, Murumägi A, Kulesskiy E, Laaksonen M, Wennerberg K, Varjosalo M, Laakkonen P, Lehtonen R, Hautaniemi H, Kallioniemi O, Schöffski P, Sihto H and Joensuu H. Anagrelide for gastrointestinal stromal tumor. Clinical Cancer Res. 25(5):1676-1687, 2019.

Le Joncour VLaakkonen P. Seek & Destroy, use of targeting peptides for cancer detection and drug delivery. Bioorg Med Chem. S0968-0896(17)31109-4, 2018.

Ylivinkka I, Sihto H, Tynninen O, Yizhou H, Laakso A, Kivisaari R, Laakkonen P, Keski-Oja J and Hyytiäinen M. Motility of glioblastoma cells is driven by netrin-1 induced gain of stemness. Journal of Experimental & Clinical Cancer Research 36(1):9, 2017.

Kaur A, Denisova O, Qiao X, Jumppanen M, Peuhu E, Ahmed S, Raheem O, Haapasalo H, Eriksson J, Chalmers A, Laakkonen P and Westermarck, J. PP2A inhibitor PME-1 drives kinase inhibitor resistance in glioma cells. Cancer Res. 76(23):7001-11, 2016.

Salmenperä P, Karhemo P-R, Räsänen K, Laakkonen, P* and Vaheri A*. Nemotic fibroblast spheroids are characterized by quiescence and ability to inhibit tumor growth. *Equal contribution. Experimental Cell Research, 345(1):17-24, 2016.

Eriksson J, Le Joncour V, Nummela P, Jahkola T, Virolainen S, Laakkonen P, Saksela O and Hölttä E. Gene expression analyses of primary melanomas reveal CTHRC1 as an important player in melanoma progression. Oncotarget 7(12):15065-92. 2016.

Hyvönen M and Laakkonen P. Identification and characterization of homing peptides using in vivo peptide phage display. Methods Mol. Biol. 1324:205-222, 2015.

Wang C-F, Sarparanta M, Mäkilä E, Hyvönen M, Laakkonen P, Salonen J, Hirvonen J, Airaksinen A and Santos H. Multifunctional porous silicon nanoparticles for cancer theranostics. Biomaterials. 48:108-18, 2015.

Hyvönen M, Enbäck J, Huhtala T, Lammi J, Sihto H, Weisell J, Joensuu H, Rosenthal Aizma, K, El-Andaloussi S, Langel U, Närvänen A, Bergers G and Laakkonen P. Mammary-derived growth inhibitor as a novel target for peptide-based imaging and treatment of brain tumors. Molecular Cancer Therapeutics, 3(4):996-1007, 2014. Editors of the journal highlighted our paper and selected our figure as the cover figure of April 2014 issue.

Kinnari P, Hyvönen M, Mäkilä E, Kaasalainen M, Rivinoja A, Salonen J, Hirvonen J, Laakkonen P* and Santos HA*. Tumor-homing peptide boosts porous silicon nanovectors accumulation in vivo. *Corresponding author. Biomaterials 34(36):9134-41, 2013.

Eriste E, Kurrikoff K, Suhorutšenko J, Oskolkov N, Copolovici D, Jones S, Laakkonen P, Howl J and Langel U. Peptide-based glioma-targeted drug delivery vector gHoPe2. Bioconjug. Chem. 24(3):305-313, 2013.

Sarek G, Enbäck J, Järviluoma A, Haas J, Gessain A, Laakkonen P* and Ojala PM*. Viral lytic replication compromises apoptotic response to p53 reactivation in KSHV lymphomas. *Corresponding author. Oncogene 32:(9)1091-1098, 2013.

Karhemo PR, Hyvönen M and Laakkonen P. Metastasis-associated cell surface oncoproteimics. Front. Pharmacol. 3:(192) 1-8, 2012.

Mäe M, Rautsi O, Enbäck J, Hällbrink M, Rosenthal A, Lindgren MK, Laakkonen P and Langel Ü. Tumour targeting with rationally modified cell-penetrating peptides. International Journal of Peptide Research and Therapeutics (IJPR) 18(4):361-371, 2012.

Karhemo PR, Ravelin S, Laakso M, Ritamo I, Tatti O, Mäkinen S, Goodison S, Stenman UH, Hölttä E, Hautaniemi S, Valmu L, Lehti K and Laakkonen P. An optimized isolation of biotinylated cell surface proteins reveals novel players in cancer metastasis. J. Prot. 77:87-100, 2012.

Nummela P, Lammi J, Soikkeli J, Saksela O, Laakkonen P and Hölttä E. Transforming Growth Factor Beta-induced (TGFBI) is an Anti-adhesive Protein Regulating the Invasive Growth of Melanoma Cells. Am. J. Pathol. 180(4):1663-74, 2012.

Karhemo PR, Rivinoja A, Lundin J, Hyvönen M, Chernenko A, Lammi J, Sihto H, Lundin M, Heikkilä P, Joensuu H, Bono P and Laakkonen P. An extensive tumor array analysis supports tumor suppressive role for nucleophosmin in breast cancer. Am. J. Pathol. 179(2):1004-14, 2011.

Rivinoja A and Laakkonen P. Identification of homing peptides using the in vivo phage display technology. Methods Mol. Biol. 683:401-415, 2011.

Laakkonen P and Vuorinen K. Homing peptides as targeted delivery vehicles. Integr. Biol. (Camb) 2(7-8):326-337, 2010.

Huhtala T, Laakkonen P, Sallinen J, Ylä-Herttuala S and Närvänen A. In vivo SPECT/CT imaging of human orthotopic ovarian carcinoma xenografts with 111In-labeled monoclonal antibodies. Nucl. Med. Biol. 37:957-964, 2010.

Peltonen K, Colis L, Liu H, Jäämaa S, Moore H, Enbäck J, Laakkonen P, Vaahtokari A, Jones RJ, af Hällström TM and Laiho M. Identification of novel p53 pathway activating small-molecule compounds reveals unexpected similarities with known therapeutic agents. PLoS One 5(9):e12996, 2010.

D’Amico G, Korhonen E, Waltari M, Saharinen P, Laakkonen P and Alitalo K. Loss of endothelial Tie1 receptor impairs lymphatic vessel development. Arterioscler Thromb Vasc Biol. 30(2):207-9, 2010.

Hekim C, Riipi T, Zhu L, Laakkonen P, Stenman, UH and Koistinen H. Complex formation between human prostate-specific antigen and protease inhibitors in mouse plasma. Prostate 70:485-490, 2010.

Koistinen H, Hautala LC, Seppälä M, Stenman UH, Laakkonen P and Koistinen R. The role of glycodelin in cell differentiation and tumor growth. Scand, J. of Clin. Lab. Invest. 69:452-459, 2009.

Mattsson JM, Laakkonen P, Stenman UH, and Koistinen H. Antiangiogenic properties of prostate-specific antigen (PSA). Scand, J. of Clin. Lab. Invest. 69:447-451, 2009.

Petrova TV, Bono P, Holnthoner W, Chesnes J, Pytowski, B, Sihto H, Laakkonen P, Heikkilä P, Joensuu H and Alitalo K. VEGFR-3 expression is restricted to blood and lymphatic vessels in solid tumors. Cancer Cell 13:554-556, 2008.

Tammela T, Zarkada G, Wallgard E, Murtomäki A, Suchting S, Wirzenius M, Waltari M, Hellström M, Schomber T, Peltonen R, Freitas C, Duarte A, Isoniemi H, Laakkonen P, Christofori G, Ylä-Herttuala S, Shibuya M, Pytowski B, Eichmann A, Betsholtz C, and Alitalo K. Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation. Nature 454:656-660, 2008.

Laakkonen P*, Zhang L and Ruoslahti E. Peptide targeting of lymph vessels. In: The Lymphatic Continuum Revisited. Stanley G. Rockson, ed., *Corresponding author. Ann. N.Y. Acad. Sci. 1131:37-43, 2008.

Hautala L, Koistinen R, Seppälä M, Butsow R, Stenman UH, Laakkonen P and Koistinen H. Glycodelin reduces breast cancer growth in vivo. Int. J. Cancer 123:2279-2284, 2008.

Mäkelä AR, Enbäck J, Laakkonen JP, Vihinen-Ranta M, Laakkonen P and Oker-Blom C. Tumor targeting of baculovirus displaying a lymphatic homing peptide. J. Gene Med. 10:1019-1031, 2008.

Mattson JM, Laakkonen P, Kilpinen S, Stenman UH and Koistinen H. Gene expression changes associated with the anti-angiogenic activity of kallikrein-related peptidase 3 (KLK3) on human umbilical vein endothelial cells. Biol. Chem. 389:765-771, 2008.

Koistinen H, Närvänen A, Pakkala M, Hekim C, Mattsson JM, Zhu L, Laakkonen P and Stenman UH. Development of peptides specifically modulating the activities of KLK2 and KLK3. Biol. Chem. 389:633-642, 2008.

Mattson JM, Valmu L, Laakkonen P, Stenman UH and Koistinen H. Structural characterization and anti-angiogenic properties of prostate-specific antigen isoforms in seminal fluid. Prostate 68:945-954, 2008.

Enbäck J and Laakkonen P. Tumour-homing peptides: tools for targeting, imaging and destruction. Biochem Soc Trans. Aug;35(Pt 4):780-3, 2007.

Sarek G, Kurki S, Enbäck J, Iotzova G, Haas J, Laakkonen P, Laiho M and Ojala PM. Reactivation of the p53 pathway as a novel treatment modality for KSHV-induced lymphomas. J. Clin. Invest. 117:1019-1028, 2007.

Laakkonen P, Waltari M, Holopainen T, Takahashi T, Pytowski B, Steiner P, Hicklin D, Persaud K, Tonra JR, Witte L and Alitalo, K. Vascular endothelial growth factor receptor 3 (VEGFR-3) is involved in tumor angiogenesis and growth. Cancer Res. 67:593-599, 2007.

Ranki T, Kanerva A, Ristimäki A, Hakkarainen T, Särkioja M, Kangasniemi L, Raki M, Laakkonen P, Goodison S and Hemminki A. A heparan sulphate targeted conditionally replicative adenovirus, ad5.pk7-∆24, for the treatment of advanced breast cancer. Gene Therapy 14:58-67, 2007.

Hattula K, Furuhjelm J, Tikkanen J, Tanhuanpää K, Laakkonen P and Peränen J. Characterization of the Rab8-apecific membrane traffic route link to protrusion formation. J. Cell Sci. 119:4866-4877, 2006.

Laakkonen P, Akerman M, Biliran H, Yang M, Ferrer F, Karpanen T, Hoffman R and Ruoslahti E. Anti-tumor activity of a homing peptide that targets tumor lymphatics and tumor cells. Proc. Natl. Acad. Sci. USA 101:9381-9386, 2004.

Kerjaschki D, Regele HM, Moosberge, I, Nagy-Bojarski K, Watschinger B, Soleiman A, Birner P, Krieger S, Hovorka A, Silberhumer G, Laakkonen P, Petrova T, Langer B and Raab I. Lymphatic neoangiogenesis in human kidney transplants is associated with immunologically active lymphocytic infiltrates. J. Am. Soc. Nephrol. 15:603-612, 2004.

Christian S, Pilch J, Akerman M, Porkka K, Laakkonen P and Ruoslahti E. Nucleolin expressed at the cell surface is a marker of endothelial cell in angiogenic blood vessels. J. Cell Biol. 163:871-878, 2003.

Joyce J*, Laakkonen P*, Bernasconi M, Berger G, Ruoslahti E and Hanahan D. Stage-specific vascular markers revealed by phage display in a mouse model of pancreatic islet tumorigenesis. *Equal contribution. Cancer Cell 4:393-403, 2003.

Matsui K, Nagy-Bojarsky K, Laakkonen P, Krieger S, Mechtler K, Geleff S, Kang DH, Johnson RJ and Kerjaschki D. Lymphatic microvessels in the rat remnant kidney model of renal fibrosis: Aminopeptidase P and podoplanin are discriminatory markers for endothelial cells of blood and lymphatic vessels. J. Am. Soc. Nephrol. 14:1981-1989, 2004.

Åkerman ME, Chan WCW, Laakkonen P, Bhatia SN and Ruoslahti E. Nanocrystal targeting in vivo. Proc. Natl. Acad. Sci. USA 99:12617-12621, 2002.

Porkka K, Laakkonen P, Hoffman JA, Bernasconi M and Ruoslahti E. A fragment of the HMGN2 protein homes to the nuclei of tumor cells and tumor endothelial cells in vivo. Proc. Natl. Acad. Sci. USA 99:7444-7449, 2002.

Laakkonen P. Porkka K, Hoffman JA and Ruoslahti E. A tumor-homing peptide with a targeting specificity related to lymphatic vessels. Nat. Med. 8:751-755, 2002.

Assa-Munt N, Jia X, Laakkonen P and Ruoslahti E. Solution structures and integrin-binding activities of an RGD peptide with two isoforms. Biochemistry 40:2373-2378, 2001.

Ahola T, Kujala P, Tuittila M, Blom T, Laakkonen P, Hinkkanen A and Auvinen P. Effects of palmitoylation of replicase protein nsp1 on alphavirus infection. J. Virol. 74:6725-6733, 2000.

Laakkonen P, Auvinen P, Kujala P and Kääriäinen L. Alphavirus replicase protein Nsp1 induces filopodia and rearrangement of actin filaments. J. Virol. 72:10265-10269, 1998.

Ahola T, Laakkonen P, Vihinen H and Kääriäinen L. Critical residues of Semliki Forest virus RNA capping enzyme involved in methyltransferase and guanylyltransferase-like activities. J. Virol. 71:392-397, 1997.

Laakkonen P, Ahola T and Kääriäinen L. The effects of palmitoylation on membrane association of Semliki Forest virus RNA capping enzyme. J. Biol. Chem. 271:28567-28571, 1996.

Russo P, Laakkonen P, Ahola T and Kääriäinen L. Synthesis of Semliki Forest virus RNA polymerase components nsP1-nsP4 in yeast by expression of cDNA encoding the nonstructural polyprotein. J. Virol. 70:4086-4089, 1996.

Peranen J, Laakkonen P, Hyvönen M and Kääriäinen L. The alphavirus replicase protein nsP1 is membrane-associated and has affinity to endocytic organelles. Virology 208:610-620, 1995.

Laakkonen P, Hyvonen M, Peranen J and Kääriäinen L. Expression of Semliki Forest virus nsP1-specific methyltransferase in insect cells and in Escherichia coli. J. Virol.  68:7418-7425, 1994.

Syväoja P (Laakkonen), Peränen J, Suomalainen M, Keränen S and Kääriäinen L. A single amino acid change in E3 of ts1 mutant inhibits the intracellular transport of SFV envelope protein complex. Virology 179:658-666, 1990.

Book Chapters (invited):

Le Joncour V and Laakkonen P. Targeting peptides, a Swiss-army knife against cancer. IN: Amino Acids, Pept. Proteins 42:280-319, The Royal Society of Chemistry, 2018.

Laakkonen P and Ruoslahti E. Selective delivery to vascular addresses: In vivo applications of cell type-specific CPPs. In: Cell-Penetrating Peptides, 2nd Edition, Ulo Langel, ed., CRC Press, 2006.

Hoffman JA, Laakkonen P, Porkka K, Bernasconi M and Ruoslahti E. In vivo and ex vivo selection using phage-displayed libraries. In: Phage Display: A Practical Approach, T. Clarkson and H. Lowman, eds. (Oxford, U.K., Oxford University Press), pp. 171-192, 2004.

Porkka K. and Laakkonen P. Ligandomics--a tool for the development of targeted treatments (in Finnish). Duodecim. 118(11):1185-92, 2002.

Patents

Ruoslahti Erkki and Laakkonen, Pirjo. "Diagnosis and treatment of brain tumor”. US 20150212086 A1. February 2017.

Laakkonen Pirjo, Ruoslahti Erkki and Bergers Gabriele “Peptide homing to brain tumors”. US 20110130342 A1. May 2012

Laakkonen Pirjo, Porkka Kimmo, Hoffman Jason A. and Ruoslahti Erkki “Peptides that home to tumor lymphatic vasculature and methods of using the same”. US 20110165083 A1, December 2012.

Hanahan Douglas, Ruoslahti Erkki, Joyce Johanna A. and Laakkonen Pirjo “Molecules that selectively home to vasculature of premalignant or malignant lesions of the pancreas and other organs”. United States Patent Application 20050245445, November 3, 2005.

Alitalo Kari, Laakkonen Pirjo, Kubo Hajime, Sainio Kirsi “Tie Receptor And Tie Ligand Materials And Methods For Modulating Female Fertility”. WO2006002854, January 12, 2006.